Teva Pharma Industries Stock Working Capital
| TEVA Stock | USD 16.10 0.14 0.86% |
Teva Pharma Industries fundamentals help investors to digest information that contributes to Teva Pharma's financial success or failures. It also enables traders to predict the movement of Teva Stock. The fundamental analysis module provides a way to measure Teva Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Teva Pharma stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | -244 M | -256.2 M | |
| Change In Working Capital | -435 M | -413.2 M |
Teva | Working Capital |
Teva Pharma Industries Company Working Capital Analysis
Teva Pharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Teva Pharma Working Capital | (244 M) |
Most of Teva Pharma's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Teva Pharma Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Teva Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Teva Pharma is extremely important. It helps to project a fair market value of Teva Stock properly, considering its historical fundamentals such as Working Capital. Since Teva Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Teva Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Teva Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Teva Capital Surpluse
Capital Surpluse |
|
Based on the company's disclosures, Teva Pharma Industries has a Working Capital of (244 Million). This is 157.32% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The working capital for all United States stocks is 116.51% higher than that of the company.
Teva Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Teva Pharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Teva Pharma could also be used in its relative valuation, which is a method of valuing Teva Pharma by comparing valuation metrics of similar companies.Teva Pharma is currently under evaluation in working capital category among its peers.
Teva Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Teva Pharma from analyzing Teva Pharma's financial statements. These drivers represent accounts that assess Teva Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Teva Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 16.0B | 10.8B | 9.6B | 25.3B | 22.8B | 13.9B |
Teva Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Teva Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Teva Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Teva Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | 0.0509 | ||||
| Profit Margin | (0.1) % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 33.4 B | ||||
| Shares Outstanding | 1.15 B | ||||
| Shares Owned By Institutions | 60.32 % | ||||
| Number Of Shares Shorted | 27.81 M | ||||
| Price To Earning | 15.67 X | ||||
| Price To Book | 3.47 X | ||||
| Price To Sales | 1.13 X | ||||
| Revenue | 16.54 B | ||||
| Gross Profit | 8.06 B | ||||
| EBITDA | (303 M) | ||||
| Net Income | (1.96 B) | ||||
| Cash And Equivalents | 2.22 B | ||||
| Cash Per Share | 2.00 X | ||||
| Total Debt | 18.08 B | ||||
| Debt To Equity | 2.27 % | ||||
| Current Ratio | 0.99 X | ||||
| Book Value Per Share | 4.74 X | ||||
| Cash Flow From Operations | 1.25 B | ||||
| Short Ratio | 1.85 X | ||||
| Earnings Per Share | (1.45) X | ||||
| Price To Earnings To Growth | 0.98 X | ||||
| Target Price | 23.56 | ||||
| Number Of Employees | 33.89 K | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 18.65 B | ||||
| Total Asset | 39.33 B | ||||
| Retained Earnings | (15.17 B) | ||||
| Working Capital | (244 M) | ||||
| Current Asset | 18.4 B | ||||
| Current Liabilities | 13.01 B | ||||
| Five Year Return | 2.95 % | ||||
| Net Asset | 39.33 B |
About Teva Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Teva Pharma Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Teva Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Teva Pharma Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out Teva Pharma Piotroski F Score and Teva Pharma Altman Z Score analysis. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (1.45) | Revenue Per Share | Quarterly Revenue Growth (0.05) | Return On Assets |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.